Fertility preservation in females requiring gonadotoxic therapy should be more than freezing measures before therapy – secondary fertility preservation and menopause care management after therapy should also be considered
Archives of Gynecology and Obstetrics · 2025
DOI: 10.1007/s00404-025-08104-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Gynecology and Obstetrics, 2025. Verfasst von Michael von Wolff und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynaecological Endocrinology and Reproductive Medicine, University Women's Hospital, Inselspital, Friedbühlstrasse 19, 3010, Bern, Switze…. Hauptthemen laut MEDLINE: Fertility Preservation, Ovarian Reserve, Menopause, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bern.
Abstract (Originalsprache)
To date, fertility preservation has mainly been offered to patients prior to gonadotoxic treatment. Ovarian reserve is assessed by analysing blood levels of anti-müllerian hormone (AMH), and gonadal cells or tissue are cryopreserved if indicated and requested by the patient. If primary fertility preservation (Primary FertiProtekt) before gonadotoxic treatment was not performed or was ineffective, secondary fertility preservation should be considered approximately one year after treatment based on a more extensive ovarian reserve analysis including menstrual cycle pattern, antral follicle count, and serum levels of AMH, estradiol and follicle stimulating hormone. Ovarian reserve analysis is also required to consider endocrine treatment in (pre) menopausal patients. Both approaches require the fertility preservation treatment to be tailored to the ovarian reserve status, type of gonadotoxic therapy. For secondary fertility preservation (Secondary FertiProtekt), oocyte freezing may be considered if ovarian reserve is not too low. Monthly treatment cycles, natural cycle or minimal stimulation protocols and follicle aspiration without anesthesia should be preferred. Menopause care management (MenoProtekt) involves acute menopausal symptom relief and prevention of chronic non-communicable diseases. The management needs to be individualized based on type of disease (hormone-dependent or -independent).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gynaecological Endocrinology and Reproductive Medicine, University Women's Hospital, Inselspital, Friedbühlstrasse 19, 3010, Bern, Switzerland. michael.vonwolff@insel.ch.
- Department of Pelvic Cancer, Unit of Gynecologic Oncology, Karolinska University Hospital, Stockholm, Sweden.
- Division of Gynaecological Endocrinology and Reproductive Medicine, University Women's Hospital, Inselspital, Friedbühlstrasse 19, 3010, Bern, Switzerland.
Förderung
- University of Bern
Zitieren
APA
von Wolff, M., Imboden, S., & Stute, P. (2025). Fertility preservation in females requiring gonadotoxic therapy should be more than freezing measures before therapy – secondary fertility preservation and menopause care management after therapy should also be considered. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-025-08104-5
Vancouver
von Wolff M, Imboden S, Stute P. Fertility preservation in females requiring gonadotoxic therapy should be more than freezing measures before therapy – secondary fertility preservation and menopause care management after therapy should also be considered. Archives of Gynecology and Obstetrics. 2025. doi:10.1007/s00404-025-08104-5
BibTeX
@article{vonWolff2025,
author = {von Wolff, Michael and Imboden, Sara and Stute, Petra},
title = {Fertility preservation in females requiring gonadotoxic therapy should be more than freezing measures before therapy – secondary fertility preservation and menopause care management after therapy should also be considered},
journal = {Archives of Gynecology and Obstetrics},
year = {2025},
doi = {10.1007/s00404-025-08104-5}
}
EUVIMED